14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
REGN vs AMGN
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
REGN vs AMGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AMGN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)
AMGN Overall Winner
6-Pillar Tally: REGN 3 – 3 AMGN
Matrix Metrics: REGN 5 – 5 AMGN
As of Nov 19, 2026, Amgen Inc (AMGN) is the stronger overall head-to-head candidate over Regeneron Pharmaceuticals Inc (REGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas AMGN carries 48.4/100 (HOLD) at $438.82 (17.5x Forward P/E, 34.1% operating margin).
Growth vs. Quality Trade-Off: AMGN earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. REGN 42.6/100 HOLD) and 0.47β · 26% Vol risk profile, whereas REGN leads top-line expansion (+36.3% YoY revenue growth, 1.15x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
REGN
NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
Market Cap
$97.8B
TTM Revenue
$16.9B
Forward P/E
14.9x
Beta / 30D Vol
0.32β · 55% Vol
Unified Composite Score
42.6 / 100
HOLD
Tech 19.0
Fund 45.0
Flow 68.0
Mom 56.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97
AMGN
NASDAQ
Head-to-Head Winner
Amgen Inc
Biological Products, (No Disgnostic Substances)
Market Cap
$240.1B
TTM Revenue
$38.9B
Forward P/E
17.5x
Beta / 30D Vol
0.47β · 26% Vol
Unified Composite Score
48.4 / 100
HOLD
Tech 31.0
Fund 47.0
Flow 68.0
Mom 46.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.8 · SMA20: $458.53 · SMA50: $429.28
6-Pillar Scorecard Institutional Category Breakdown (REGN 3 – 3 AMGN)
Columns: Metric · REGN · AMGN
1. Valuation Multiples
REGN
Forward P/E
14.9x
17.5x
Trailing P/E
20.9x
25.7x
PEG Ratio
1.15x
2.76x
EV / Revenue
5.7x
7.2x
2. Growth & Scale
REGN
Revenue Growth (YoY)
+36.3%
+8.5%
Earnings Growth (YoY)
+35.5%
+19.4%
TTM Revenue (USD)
$16.9B
$38.9B
Market Cap
$97.8B
$240.1B
3. Profitability & Quality
AMGN
Gross Margin
46.7%
72.5%
Operating Margin
30.4%
34.1%
Net Profit Margin
28.5%
24.1%
Return on Equity (ROE)
14.9%
78.3%
4. Balance Sheet & Cash Flow
AMGN
Cash Generation (TTM)
$3.63B
$9.58B
Cash Flow Margin
21.5%
24.6%
Net Cash / Leverage
$952M Net Cash
$40.8B Net Debt (3.76x D/E)
Dividend Yield
0.39%
2.17%
5. Options & Positioning
REGN
Options Structure Phase
CONSOLIDATION
CONSOLIDATION
Current IV / %ile
35.5% (6th %ile)
33.8% (6th %ile)
Put/Call OI Skew
0.47x (Call-Skewed)
0.59x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Markup
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
AMGN
OpEx & R&D Intensity
16.3% of Rev ($2.75B)
38.4% of Rev ($14.9B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - General Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: REGN (5) vs AMGN (5)
Institutional Metric
REGN
AMGN
Criterion
Row Edge
Market Capitalization
Scale
$97.8B
$240.1B
Larger Scale
AMGN
Trailing P/E Ratio
Valuation
20.9x
25.7x
Lower Multiple
REGN
Forward P/E Ratio
Valuation
14.9x
17.5x
Lower Multiple
REGN
Revenue Growth (YoY)
Growth
+36.3%
+8.5%
Higher Growth
REGN
Operating Margin (TTM)
Profitability
30.4%
34.1%
Higher Margin
AMGN
Net Profit Margin
Profitability
28.5%
24.1%
Higher Margin
REGN
Return on Equity (ROE)
Capital Efficiency
14.9%
78.3%
Higher ROE
AMGN
52-Week Range Position
Momentum
83% ($592–$992)
74% ($312–$484)
Stronger Trend
REGN
Beta / 30D Volatility
Risk Regime
0.32β · 55% Vol
0.47β · 26% Vol
Lower Realized Risk
AMGN
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD)
48.4 / 100 (HOLD)
Higher Composite
AMGN
Trailing 12M Revenue (USD)
Operating Scale
$16.9B
$38.9B
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7%
72.5%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.15x PEG · 5.7x EV/Rev
2.76x PEG · 7.2x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.63B ($952M Net Cash)
$9.58B ($40.8B Net Debt (3.76x D/E))
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
REGN +14.5 pp
REGN:
+14.61%
·
AMGN:
+0.11%
3M Horizon
REGN +10.83 pp
REGN:
+10.71%
·
AMGN:
-0.12%
6M Horizon
REGN +13.64 pp
REGN:
+43.69%
·
AMGN:
+30.05%
1Y Horizon
AMGN +0.27 pp
REGN:
+27.3%
·
AMGN:
+27.57%
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
Split-Invariant USD Revenue & Operating Margin (%)
Period
REGN Revenue
AMGN Revenue
REGN Op. Margin
AMGN Op. Margin
Margin Leader
FY2018
$5.15B
$23.8B
49.3%
43.2%
REGN
FY2019
$6.56B
$23.4B
33.7%
41.4%
AMGN
FY2020
$8.50B
$25.4B
42.1%
35.9%
REGN
FY2021
$16.1B
$26.0B
55.7%
29.4%
REGN
FY2022
$12.2B
$26.3B
38.9%
36.3%
REGN
FY2023
$13.1B
$28.2B
30.9%
28.0%
REGN
FY2024
$14.2B
$33.4B
28.1%
21.7%
REGN
FY2025
$14.3B
$36.8B
24.9%
24.7%
REGN
REGN
CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV
35.5%
IV Percentile
6th %ile
Put/Call OI Skew
0.47x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
AMGN
CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV
33.8%
IV Percentile
6th %ile
Put/Call OI Skew
0.59x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
5-DAY BULLISH SWING
Liq C
Dec 18 $950 / $1,000 Bull Call Spread
Buy 1x $950C · Sell 1x $1,000C · 31d
Net Entry
$2,387 Debit
T+5d @ +5% Move
+$891 (+37%)
Max Risk / Buffer
$2,387 Capped
5d Edge & Liquidity
0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME
Liq C
Jan 15 '27 $880 / $820 Bull Put Spread
Sell 1x $880P · Buy 1x $820P · 59d
Net Entry
$1,367 Credit
Max Credit / Yield
+$1,367 (+29.5% RoM)
Max Risk / Buffer
-9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity
75% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY BULLISH SWING
Liq A
Dec 18 $460 / $480 Bull Call Spread
Buy 1x $460C · Sell 1x $480C · 31d
Net Entry
$980 Debit
T+5d @ +5% Move
+$431 (+44%)
Max Risk / Buffer
$980 Capped
5d Edge & Liquidity
0.8x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME
Liq A
Dec 18 $440 / $420 Bull Put Spread
Sell 1x $440P · Buy 1x $420P · 31d
Net Entry
$373 Credit
Max Credit / Yield
+$373 (+22.9% RoM)
Max Risk / Buffer
-5.6% Cushion ($1,627 Mgn)
5d Edge & Liquidity
75% PoP · Liq A
Simulate 5-Day Payoff →
REGN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment
16.3% of Rev ($2.75B)
90D Engineering Disclosures
0 Published
AMGN Moat Profile
High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $240.1B market capitalization and 34.1% operating margin.
OpEx & R&D Reinvestment
38.4% of Rev ($14.9B)
90D Engineering Disclosures
0 Published
Investor FAQ REGN vs AMGN Key Questions & Quantitative Answers
Is REGN or AMGN a better stock to buy right now?
As of Nov 19, 2026, Amgen Inc (AMGN) is the stronger overall head-to-head candidate over Regeneron Pharmaceuticals Inc (REGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas AMGN carries 48.4/100 (HOLD) at $438.82 (17.5x Forward P/E, 34.1% operating margin). Growth vs. Quality Trade-Off: AMGN earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. REGN 42.6/100 HOLD) and 0.47β · 26% Vol risk profile, whereas REGN leads top-line expansion (+36.3% YoY revenue growth, 1.15x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Does REGN or AMGN have stronger revenue and earnings growth?
REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with AMGN at +8.5% YoY revenue growth and +19.4% YoY earnings growth on $38.9B TTM revenue (72.5% gross margin, 34.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), REGN cumulative revenue shifted +178.4% while AMGN shifted +54.7%. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus 38.4% of Rev ($14.9B) (0 disclosures) for AMGN.
Is REGN or AMGN cheaper on valuation?
REGN screens cheaper on headline valuation multiples. REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin), whereas AMGN trades at 17.5x Forward P/E, 25.7x Trailing P/E, 2.76x PEG, and 7.2x EV/Revenue (24.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus AMGN (78.3% ROE) capital efficiency.
How is options market volatility positioned on REGN vs AMGN?
In options market volatility and institutional positioning, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk). By comparison, AMGN carries 33.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.59x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.47β · 26% Vol realized risk).
Regeneron Pharmaceuticals Inc (REGN) Research Suite
Amgen Inc (AMGN) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.